Zacks: Analysts Expect Magenta Therapeutics Inc (MGTA) Will Announce Earnings of -$0.55 Per Share

Wall Street analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce earnings per share (EPS) of ($0.55) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Magenta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.55) and the highest estimate coming in at ($0.54). The business is scheduled to announce its next quarterly earnings report on Thursday, February 28th.

On average, analysts expect that Magenta Therapeutics will report full year earnings of ($3.19) per share for the current year, with EPS estimates ranging from ($3.23) to ($3.15). For the next financial year, analysts expect that the firm will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.67) to ($1.12). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Magenta Therapeutics.

A number of equities analysts recently issued reports on MGTA shares. Zacks Investment Research upgraded shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 13th. ValuEngine lowered shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.33.

Several large investors have recently bought and sold shares of the company. Two Sigma Investments LP bought a new stake in shares of Magenta Therapeutics in the 4th quarter valued at $104,000. Casdin Capital LLC raised its holdings in Magenta Therapeutics by 17.4% during the fourth quarter. Casdin Capital LLC now owns 2,643,317 shares of the company’s stock worth $15,067,000 after buying an additional 392,499 shares during the last quarter. Geode Capital Management LLC raised its holdings in Magenta Therapeutics by 42.9% during the fourth quarter. Geode Capital Management LLC now owns 21,739 shares of the company’s stock worth $123,000 after buying an additional 6,525 shares during the last quarter. Bessemer Group Inc. acquired a new position in Magenta Therapeutics during the fourth quarter worth $1,352,000. Finally, Northern Trust Corp raised its holdings in Magenta Therapeutics by 21.8% during the fourth quarter. Northern Trust Corp now owns 66,414 shares of the company’s stock worth $378,000 after buying an additional 11,893 shares during the last quarter. 57.85% of the stock is currently owned by institutional investors.

MGTA stock traded up $1.91 during trading on Tuesday, reaching $15.02. 154,207 shares of the company were exchanged, compared to its average volume of 62,559. Magenta Therapeutics has a twelve month low of $5.31 and a twelve month high of $16.33.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Recommended Story: What is a recession?

Get a free copy of the Zacks research report on Magenta Therapeutics (MGTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit